Medicine and Dentistry
Radiation Therapy
100%
Lung Cancer
92%
Neoplasm
69%
Non Small Cell Lung Cancer
69%
Adaptive Radiotherapy
52%
Lymph Node
46%
Esophageal Cancer
43%
Proton Therapy
40%
Radiation Therapy
37%
Volume CT
37%
Intensity Modulated Radiation Therapy
32%
Overall Survival
31%
Clinical Trial
28%
Non-Small Cell Lung Cancer
23%
Chemoradiotherapy
21%
Radiation Pneumonia
20%
Photon Therapy
19%
Recurrent Disease
17%
Mediastinal Lymph Node
16%
Stereotactic Body Radiation Therapy
16%
Squamous Cell Carcinoma
16%
Radiotherapy of Lung Cancer
16%
Hazard Ratio
14%
Arm
13%
Pulmonary Toxicity
12%
Dose Calculation
12%
Radiation Dose Escalation
12%
Malignant Neoplasm
12%
Single-Photon Emission Computed Tomography
11%
Cone Beam Computed Tomography
11%
Positron Emission Tomography-Computed Tomography
10%
Progression Free Survival
10%
Radiation Therapy Techniques
9%
Pelvis
9%
Breathing
9%
Trachea
9%
Lung Tumor
9%
Breast Cancer
8%
Main Bronchus
8%
Oxygen Consumption
8%
Chest
8%
Coronary Artery Disease
8%
Treatment of Lung Cancer
8%
Coronary Artery
8%
Heart Function
8%
Isotopes of Calcium
8%
Relative Biologic Effectiveness
8%
Esophageal Cancer
8%
Phase III Trials
8%
Subgroup Analysis
8%
Pharmacology, Toxicology and Pharmaceutical Science
Lung Cancer
86%
Neoplasm
59%
Non Small Cell Lung Cancer
52%
Overall Survival
30%
Esophagus Cancer
16%
Lung Tumor
16%
Malignant Neoplasm
13%
Recurrent Disease
12%
Clinical Trial
12%
Primary Tumor
10%
Chemoradiation Therapy
9%
Squamous Cell Carcinoma
8%
Lung Toxicity
8%
Radiation Pneumonia
8%
Prostate Cancer
8%
Phase III Trials
8%
Small Cell Lung Cancer
8%
Diseases
8%
Bleeding
7%
Progression Free Survival
5%
Cancer Specific Survival
5%
Keyphrases
Radiotherapy Quality Assurance
16%
Target Definition
8%
Dose-escalation Trial
8%
Interfractional Changes
8%
Metabolic Tumor Response
8%
Combined Chemoradiotherapy
8%
Planning Target Volume
8%
Respiratory Motion
8%
FDG PET-CT
8%
Radical Radiotherapy
8%
Local Failure
8%
Constrained Inference
8%
Intensity-modulated Proton Therapy
8%
Tumor Response Assessment
8%
Dose-volume Histogram
8%
Dose Constraints
8%
T3N0M0
8%
Medically Inoperable
8%
Early Toxicity
8%
Extensive-stage Small Cell Lung Cancer (ES-SCLC)
8%
Clinical Trials
8%
Cohort Size
7%
Overdosage
5%
Photon Therapy
5%
Underdosage
5%
Adaptive Transmission
5%
